Plasma apelin concentration is depressed following acute myocardial infarction in man.
OBJECTIVE
Apelin, a novel peptide with a putative role in cardiovascular homeostasis, has gained interest as an endogenous inotrope, but has yet to be described following acute myocardial infarction (AMI) in man. We aimed to characterize plasma apelin concentrations following AMI and to examine its relationship with clinical and prognostic biomarkers.


RESULTS
Plasma concentrations of apelin, N-terminal probrain natriuretic peptide (NT-proBNP), norepinephrine, and arginine vasopressin were measured in 100 patients [mean age 58.9 +/- 12 (SD) years, 77% male] admitted with AMI, with echocardiographic left ventricular (LV) ejection fraction <40%, at mean 46 h after admission and at 24 weeks. Cardiac magnetic resonance imaging was performed pre-discharge and at 24 weeks. Thirty-eight subjects with no cardiac history acted as controls. Apelin concentration was reduced early after AMI (0.54 +/- 0.25 vs. 3.22 +/- 3.01 ng/mL, P <0.001) and remained low at 24 weeks, although it did increase significantly from baseline to 0.62 +/- 0.36 ng/mL, P = 0.030. Apelin had no relationship with any parameter of LV function over time. A relationship was found between baseline apelin and norepinephrine (r = 0.26, P = 0.008). Both NT-proBNP and norepinephrine correlated with adverse ventricular function after AMI.


CONCLUSIONS
Plasma apelin concentration is reduced early after AMI, increases significantly over time, but remains depressed at 24 weeks.
Weir
Robin A P
RA
Cardiology Department, Western Infirmary, Glasgow G11 6NT, Scotland, UK. robinweir75@hotmail.com
Chong
Kwok Shiong
KS
Dalzell
Jonathan R
JR
Petrie
Colin J
CJ
Murphy
Charles A
CA
Steedman
Tracey
T
Mark
Patrick B
PB
McDonagh
Theresa A
TA
Dargie
Henry J
HJ
McMurray
John J V
JJ
D000073861:Apelin; D015415:Biomarkers / Q000097:blood; D002851:Chromatography, High Pressure Liquid; D004311:Double-Blind Method; D004452:Echocardiography; D000077545:Eplerenone; D005260:Female; D005500:Follow-Up Studies; D006352:Heart Ventricles / Q000000981:diagnostic imaging / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood*; D008024:Ligands; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D011379:Prognosis; D013148:Spironolactone / Q000031:analogs & derivatives / Q000627:therapeutic use; D013318:Stroke Volume; D018487:Ventricular Dysfunction, Left / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D020257:Ventricular Remodeling / Q000502:physiology*
C115436:APLN protein, human; D000073861:Apelin; D015415:Biomarkers; D036341:Intercellular Signaling Peptides and Proteins; D008024:Ligands; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000077545:Eplerenone